D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia.
Behavioral: Cognitive retraining
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||D-Serine Augmentation of Cognitive Retraining in Schizophrenia|
- Positive and Negative Syndrome Scale (PANSS) [ Designated as safety issue: Yes ]
- Wisconsin Card Sorting Test (WCST) [ Designated as safety issue: No ]
- Hopkins Verbal Learning Test [ Designated as safety issue: No ]
- Spatial working memory task [ Designated as safety issue: No ]
- Heinrichs-Carpenter Quality of Life Scale [ Designated as safety issue: No ]
- Neurocognitive training tasks [ Designated as safety issue: No ]
- Functional assessments [ Designated as safety issue: No ]
|Study Start Date:||February 2005|
This study is based on the hypothesis that by increasing NMDA receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.
Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00237848
|National Institute of Mental Health and Neurosciences|
|Bangalore, Karnataka, India, 560029|
|Principal Investigator:||Deepak C. D'Souza, MD||Yale University|